imagable lumiprobe cy7 maleimide dye  (Lumiprobe)

Journal: Science Advances

Article Title: Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer

doi: 10.1126/sciadv.aeb9764

Figure Lengend Snippet: ( A ) Scheme of SH-EM-NP/EPI preparation. ( B ) Sizes and zeta potential of PLGA-NP/EPI, EM-NP/EPI, and SH-EM-NP/EPI. Data are presented as the means ± SD ( n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. *** P < 0.001; **** P < 0.0001. ( C ) A representative image of SH-EM-NP/EPI examined by TEM. Scale bar, 50 nm. ( D ) Free thiol content of nanoparticles with and without SH modification measured by the DTNB (Ellman’s reagent) assay ( n = 3). ( E ) Schematic diagram of SH-EM-NP/EPI labeled with Cy7-Mal. ( F ) Fluorescence images and corresponding mean fluorescence intensities of EM-NP/EPI and SH-EM-NP/EPI after 2 hours of incubation with Cy7-Mal, followed by centrifugation, washing, and resuspension ( n = 3). ( G ) The heatmap presents the abundance profiles of the top 50 high-abundance membrane proteins across the three independent SH-EM-NP/EPI sample batches. ( H ) Photos of SH-EM-NP/EPI lyophilized powder (left) and reconstituted solution (right). All samples were stored in nitrogen atmosphere. ( I ) Size of freshly prepared solution (FS) and reconstituted solution (RS) ( n = 3). ( J ) Free thiol content of FS and RS ( n = 3). In (D), (F), (I), and (J), the data are presented as the means ± SD. Statistical analysis was performed using two-tailed Student’s t test. **** P < 0.0001; n.s., not significant.

Article Snippet: Cy7 maleimide (CAS: 2120392-49-4) and Cy7 NHS Ester (CAS: 1432019-64-1) were purchased from MedChemExpress LLC (New Jersey, USA).

Techniques: Zeta Potential Analyzer, Modification, Labeling, Fluorescence, Incubation, Centrifugation, Membrane, Two Tailed Test

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet: (A) Amino acid substitutions in m276-SL. (B) Chemical structure of m276-SL-PBD linker and warhead: maleimide (green), PEG-4 spacer (blue), and cathepsin-B-cleavablevaline-alanine dipeptide (red). The gray cloud indicates the cleavable amide group. (C–E) Cell viability assays were used to measure the activity of m276-SL-PBD and m276-glyco-PBD against the parent 293 (CD276 wild type) or 293-CD276 KO (CD276 knockout) (C), HCT116 colon cancer (D), or UACC melanoma cells (E). Error bars denote SD. (F–I) Subcutaneous growth of HCT-116 (F) and UACC (H) tumors and corresponding Kaplan-Meier survival curves (HCT116, G; UACC, I). ADC treatments were initiated when tumors reached an average size of ~750 mm 3 and were administered on the days shown (red arrows); n = 8–30/group; p values: t test (F and H) and log-rank test (G and I). Median survival is indicated for arms with <50% of animals alive at study end. Error bars denote SEM. n.s., non-significant.

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques: Activity Assay, Knock-Out

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet: (A) In vivo fluorescence imaging of Cy7-labeled m276 antibodies in JIMT tumor-bearing mice at 4, 24, 48, and 72 h post injection. Side-view images of the tumor flank are shown. An example of tumor and liver fluorescence is highlighted (white and yellow regions of interest [ROIs], respectively). (B) SEC monitoring of m276-SL-PBD samples with high-aggregate (HA) and low-aggregate (LA) composition pre- and post purification by SEC. Size standards are shown at the top. (C) Body weights in CD276-WT and -KO mice after three treatments (red arrows) with 2 mg/kg of LA and HA ADC samples from (B). Student’s t test; *p < 0.05 for m276-SL-PBD-LA in WT versus KO and m276-SL-PBD-HA in WT versus KO; n = 8–15/group. (D and E) Cell viability assays measured the activity of m276-SL-PBD pre- and post-HIC purification against HEK293 CD276-WT, CD276-KO (D), or CD276 + SUM159 breast cancer cells (E). HIC-enriched DAR1, DAR2, and DAR2-tail fractions were tested (see ). Error bars denote SD.

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques: In Vivo, Fluorescence, Imaging, Labeling, Injection, Purification, Activity Assay

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet:

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques:

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques: Recombinant, Fluorescence, Blocking Assay, Plasmid Preparation, Expressing, Software

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet: (A) In vivo fluorescence imaging of Cy7-labeled m276 antibodies in JIMT tumor-bearing mice at 4, 24, 48, and 72 h post injection. Side-view images of the tumor flank are shown. An example of tumor and liver fluorescence is highlighted (white and yellow regions of interest [ROIs], respectively). (B) SEC monitoring of m276-SL-PBD samples with high-aggregate (HA) and low-aggregate (LA) composition pre- and post purification by SEC. Size standards are shown at the top. (C) Body weights in CD276-WT and -KO mice after three treatments (red arrows) with 2 mg/kg of LA and HA ADC samples from (B). Student’s t test; *p < 0.05 for m276-SL-PBD-LA in WT versus KO and m276-SL-PBD-HA in WT versus KO; n = 8–15/group. (D and E) Cell viability assays measured the activity of m276-SL-PBD pre- and post-HIC purification against HEK293 CD276-WT, CD276-KO (D), or CD276 + SUM159 breast cancer cells (E). HIC-enriched DAR1, DAR2, and DAR2-tail fractions were tested (see ). Error bars denote SD.

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques: In Vivo, Fluorescence, Imaging, Labeling, Injection, Purification, Activity Assay

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet:

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques:

Journal: Cell reports

Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

doi: 10.1016/j.celrep.2023.113503

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: For Cy7 labeling on S239C a partial oxidation was performed using 100-fold molar excess dehydroascorbic acid before Lumiprobe Cy7 maleimide was added.

Techniques: Recombinant, Fluorescence, Blocking Assay, Plasmid Preparation, Gene Expression, Software